Related Experiment Video

Updated: Jul 28, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

CDKN2B-AS1 as a novel therapeutic target in cancer: Mechanism and clinical perspective

Ahmed Hjazi1, Eishah Ghaffar2, Waqas Asghar3

  • 1Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.

Biochemical Pharmacology
|May 31, 2023
PubMed

Insights

Long non-coding RNA CDKN2B-AS1 is elevated in many cancers and impacts key pathways. This RNA shows promise as a diagnostic and therapeutic target for cancer treatment.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • Long non-coding RNAs (lncRNAs) are crucial regulators of gene expression, influencing transcription, epigenetics, and translation.
  • Cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) is a lncRNA significantly upregulated in various cancer types.

Purpose of the Study:

  • To review recent findings on the role of CDKN2B-AS1 in cancer development.
  • To explore the potential of CDKN2B-AS1 as a diagnostic and prognostic biomarker.
  • To investigate its therapeutic implications in cancer treatment.

Main Methods:

  • Literature review of studies on CDKN2B-AS1 function in cancer.
  • Analysis of signaling pathways modulated by CDKN2B-AS1.
  • Evaluation of its role in cell proliferation, apoptosis, cell cycle, EMT, invasion, and migration.

Main Results:

  • CDKN2B-AS1 is implicated in critical cancer-associated biological pathways.
  • Its modulation affects cell proliferation, apoptosis, cell cycle, and epithelial-mesenchymal transition (EMT).
  • CDKN2B-AS1 influences cancer invasion and migration through various signaling axes.

Conclusions:

  • CDKN2B-AS1 plays a significant role in cancer onset and progression.
  • It holds considerable potential as a biomarker for cancer diagnosis and prognosis.
  • CDKN2B-AS1 represents a promising therapeutic target for novel cancer treatments.
Keywords:
CDKN2B-AS1CancerLncRNANcRNA

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.5K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

483

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K